Oricell Therapeutics

Private

Chinese clinical-stage biotech developing next-generation CAR-T cell therapies for solid tumors. Lead asset Ori-C101 targets hepatocellular carcinoma (liver cancer), aiming to become the first globally-approved CAR-T for the disease. Pipeline focused on overcoming the historical limitations of CAR-T in solid tumors.

Founders Hao Wang
CEO Hao Wang

Company

Founded
2019
Headquarters
Shanghai, China

Financials

Total Funding
$270M
Sectors
Healthtech Biotech
www.oricell.com

Funding History

4 rounds
Series D Apr 10, 2026
$110M
Vivo Capital (Lead) Beijing Medical and Health Care Industry Investment Fund Qiming Venture Partners USA E-Town Capital Luxin Venture Capital NGS Super Elikon Investment Talon Capital
Series C Jan 1, 2026
$70M
Vivo Capital (Lead) Qiming Venture Partners USA E-Town Capital
Series B Aug 1, 2022
$60M
Vivo Capital (Lead) Qiming Venture Partners USA
Series A Dec 1, 2020
$30M
Qiming Venture Partners USA (Lead)

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.